Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 1/5/2004
Phase: IV
A randomized, open-label, multi-center, efficacy and safety study of Pegasys as a prophylaxis against hepatitis C virus infection recurrence after liver transplantation.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 1/27/2004
Phase: IV
A randomized, partially blinded, multi-center, Phase II study investigating the efficacy and safety of Pegasys and Pegasys with Ribavirin in treatment-naïve patients with chronic hepatitis C co-infected with human immunodeficiency virus.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/1/2004
Phase: III
A Phase III Partially Double-Blind Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS) Combined With Placebo or Lamivudine Versus Lamivudine in HBeAg-Negative Patients With Chronic Hepatitis B (CHB)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 3/1/2004
Phase: IV
A multicentre, randomized, safety and efficacy clinical trial to evaluate the effects of the duration of treatment with peginterferon alfa-2a and ribavirin in naïve patients with chronic infection by hepatitis C virus and without an early virologic response
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 3/1/2004
Phase: III
The drug interaction companion protocol to NR15961: A randomized, partially blinded, multicenter, phase III, three arm study evaluating the efficacy and safety of peginterferon alfa-2a monotherapy versus combination therapy of peginterferon alfa-2a with ribavirin versus combination therapy of interferon alfa-2a with ribavirin for 48 weeks and 24 weeks of follow-up in patients with chronic hepatitis C coinfected with human immunodeficiency virus.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 4/29/2004
Phase: III
APRICOT study. A Randomized, Partially Blinded, Multicenter, Phase III, 3-Arm Study Evaluating the Efficacy and Safety of Peginterferon alfa-2a (40KD) Monotherapy Versus Combination Therapy of Peginterferon alfa-2a (40KD) With Ribavirin Versus Combination Therapy of Interferon alfa-2a (IFN alfa-2a) With Ribavirin for 48 Weeks and 24 Weeks of Follow-up in Patients With Chronic Hepatitis C (CHC) Co-infected With Human Immunodeficiency Virus (HIV)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 6/1/2004
Phase: III
A Phase III Partially Double-Blinded Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS) Combined With Placebo or Lamivudine Versus Lamivudine in HBeAg-Positive Patients With Chronic Hepatitis B
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 6/28/2004
Phase: IV
Peginterferon alfa-2a in combination with ribavirin in patients with chronic hepatitis C not previously treated with interferon and ribavirin: a randomized, open-label study in patients with genotype 1 evaluating the efficacy and safety of a treatment duration of 24 weeks versus 48 weeks and an observational study in patients with genotype non-1
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 11/16/2004
Phase: IV
A prospective, randomized, multicenter, open-label, comparative safety study of Pegasys vs Pegasys plus Ribavirin treatment in patients with chronic hepatitis C virus
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/15/2005
Phase: IV
Comparison of the efficacy and safety of 2 treatments regimens given for 22 weeks: Peginterferon alfa-2a (Pegasys) with ribavirin versus Pegasys alone in naïve patients with chronic hepatitis C and genotype 1 responding after a 24-week therapy of Pegasys in combination with ribavirin – An open, multi-center, national, and randomized study.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 5/1/2005
Phase: IV
A multiple-dose, parallel-group, open-label study of the pharmacokinetics of Copegus (ribavirin) and Pegasys (peginterferon alfa-2a) in Blacks, Hispanics and Caucasians infected with Chronic Hepatitis C (CHC).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 5/11/2005
Phase: IV
An open-label, multicentre pilot study evaluating the efficacy and safety of high dose peginterferon alfa-2a in combination with ribavirin in patients with chronic hepatitis C, genotype 1 who did not respond to previous IFN/ribavirin combination therapy
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
OST study. A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
CEE study. A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
HELPS study. A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Combination Therapy in Patients With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) who have Participated in Previous PEGASYS trials
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Non-Responder Patients With Chronic Hepatitis C (CHC)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A prospective, randomized, multicenter, open-label, comparative safety and efficacy study of prophylactically administered pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS) vs no prophylaxis following liver transplantation for hepatitis C
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A randomised, open-label, multicentre trial evaluating the safety and efficacy of adding amantadine to a genotype-individualised peginterferon alfa-2a plus ribavirin combination therapy in treatment-naïve or relapsing chronic hepatitis C patients
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A phase IV, randomised, multicentre, efficacy and safety study examining the effect of induction dosing with the combination of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C infected with hepatitis C genotype 1
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A multicenter, randomized, open label study comparing the efficacy and safety of 48 weeks of 40KD pegylated interferon alfa-2a (PEGASYS) versus 72 weeks of PEGASYS in naïve patients with HBeAg-negative chronic hepatitis
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A pilot, open-label, multicentre trial evaluating the safety and effect on viral clearance of increasing the dose of peginterferon alfa-2a in chronic hepatitis C patients infected with difficult-to-treat genotype 1/4/5/6 treated with peginterferon alfa-2a plus ribavirin for 12 weeks without presenting an early virological response
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A pilot, open-label, multicentre study evaluating the long-term safety and tolerability of a low-dose peginterferon alfa-2a maintenance monotherapy in chronic hepatitis C patients co-infected with human immunodeficiency virus and who do not respond to a standard regimen of peginterferon alfa-2a plus ribavirin
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients Chronic Hepatitis C (CHC) Genotype 1 and Human Immundeficiency Virus-1 (HIV-1) Co-infection, With and Without Highly Active Antiretroviral Therapy (HAART).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 9/1/2005
Phase: III
Open-label pilot study to measure early viral kinetics in patients with chronic hepatitis C infection and subtype 1 treated with (pegylated)-interferon *-2a.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
BeTTy study A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Combination Therapy in Patients With Chronic Hepatitis C (CHC)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Treatment-Naïve Patients With Chronic Hepatitis C (CHC)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection—Immunology Sub-Study of ML18253
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 11/1/2005
Phase: III
TRIPEG STUDY: Randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and tolerability of pegylated interferon alfa (PEG-IFN) plus ribavirin with and without amantadine sulfate in patients with chronic hepatitis C and subtype 1
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
Expanded Access Program A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 12/12/2005
Phase: IV
Efficacy and safety of peg-interferon alfa-2a (Pegasys) monotherapy and combination therapy with ribavirin in the treatment of genotype 4 Saudi chronic active hepatitis C patients
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of Pegylated Interferon Alfa-2a (PEGASYS) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic hepatitis B (CHB)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 12/28/2005
Phase: IV
An open-label, multicenter study evaluating the end of the follow up response predicatability at week 12 of treatment with peginterferon alfa-2a (40KD) in combination with ribavirin in patients with Chronic Hepatitis C, Genotype 1 under daily clinical practice conditions.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/1/2006
Phase: IV
Randomized, multicenter, open-label, phase IV study evaluating the efficacy and safety of 16-week versus 24-week treatment with PEGASYS in combination with Copegus in interferon-naïve patients with chronic hepatitis C genotype 2 or 3 virus infection.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of Peginterferon Alfa-2a (PEGASYS) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 4/3/2006
Phase: IV
Efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS) in patients with HBeAg positive chronic hepatitis B.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
APPROACH Study: Outcomes Assessment of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC)
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis D (CHD).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients
With Chronic Hepatitis C (CHC) Genotype 1 and Immunodeficiency Virus-1 (HIV-1) Co-infection.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 10/1/2006
Phase: IV
Randomized, multicenter, double-blind, pilot study evaluating the effect of PEGASYS doses of 180 µg or 270 µg in combination with Copegus doses of 1200 mg or 1600 mg on viral kinetics, virological response, pharmacokinetics, and safety in interferon-naïve patients with chronic hepatitis C genotype 1 virus infection of high viral titer and body weight greater than 85 kg.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 10/2/2006
Phase: III
A randomized, open-label, multicenter study evaluating the efficacy and safety of the combination therapy of peginterferon alfa-2a with Ribavirin versus combination therapy of interferon alfa-2a (Roferon-A) with Ribavirin in naïve or relapse patients with chronic hepatitis C.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study of the Influence of Ribarvirin on the Initial Viral Response in Patients With Chronic Hepatitis C (CHC).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 12/1/2006
Phase: IV
An open label, multicenter, efficacy and safety study of PEGASYS plus ribavirin in patients with chronic HCV infection who are unable to tolerate or who do not respond to 12 weeks of therapy with PEG-Intron plus ribavirin
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
TITAN Study: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/1/2007
Phase: IV
A prospective randomized, open-label study evaluating the viral kinetics and pharmacokinetics of PEGASYS plus COPEGUS and PEG-Intron plus Rebetol in interferon-naïve patients with chronic hepatitis C
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/2/2007
Phase: III
A pilot study assessing efficacy and safety of peginterferon alfa-2a (PEGASYS) versus continuation of lamivudine (LAM) and/or adefovir dipivoxil (ADV) in patients with chronic hepatitis B pre-treated with LAM and/or ADV for >6 months. An open label, multi-center, randomized, national study.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 5/29/2007
Phase: IV
Interim analysis of group D in genotype 1 / 4 study: Randomized, multicenter study to find optimal treatment duration in patients with chronic hepatitis C and subtype 1 or 4 depending on HCV RNA level at week 12.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 6/1/2007
Phase: IV
An open-label, multicenter, randomized, safety, feasibility and tolerability pilot study of PEGASYS (peginterferon alfa-2a) plus Copegus (ribavirin) in previous intravenous drug users (IVDUs) who are currently enrolled in a methadone maintenance treatment program.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
IMPROVE Study (The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 10/1/2007
Phase: IV
A Phase IV, Multicenter and Randomized Study Evaluating the Efficacy and Safety of PEG-Interferon α-2a plus Ribavirin and Amantadine or plus Ribavirin in the Treatment of Patients with Chronic Hepatitis C Previously Non Responders and Relapsers to IFNα plus Ribavirin.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 10/1/2007
Phase: II
Phase II Randomized Dose-Finding Study of Subcutaneous Administration of Three Different Doses of Pegylated Interferon alfa-2a in Patients With Metastatic Malignant Melanoma (MM).
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 12/3/2007
Phase: III
A randomized, open-label, multicenter, efficacy and safety study examining the effects of duration of treatment and of a high induction dose of PEGASYS in combination with daily Copegus in patients with chronic hepatitis C who did not respond to previous peginterferon alfa-2b/ribavirin combination therapy.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of Combination Therapy With PEGASYS (peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Virological Response.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 3/3/2008
Phase: IV
Multicenter, open-label, expanded access program of peginterferon alfa-2a monotherapy and combination therapy with ribavirin in patients with chronic hepatitis C.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 4/1/2008
Phase: III
Phase II Randomized Multicenter Comparative Study of Peginterferon alfa-2a vs. Roferon-A for the Treatment of Patients with Recently Diagnosed Chronic Phase Myelogenous Leukemia (CML) not Previously Treated with Interferon.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B.
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 4/22/2008
Phase: IV
A prospective, multicenter, open-label, comparative efficacy study of PEGASYS plus Copegus in treatment-naïve Latino patients with chronic hepatitis C-genotype 1, as compared to treatment-naïve non-Latino White patients with chronic hepatitis C-genotype 1
Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
